Last Updated: August 9, 2026

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Guaifenesin And Pseudoephedrine Hydrochloride, and what generic alternatives are available?

Guaifenesin And Pseudoephedrine Hydrochloride is a drug marketed by Actavis Labs Fl, Aurobindo Pharma Ltd, Dr Reddys, Granules, L Perrigo Co, and Sun Pharm Inds Inc. and is included in six NDAs.

The generic ingredient in GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE is guaifenesin; pseudoephedrine hydrochloride. There are twenty drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the guaifenesin; pseudoephedrine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Guaifenesin And Pseudoephedrine Hydrochloride

A generic version of GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE was approved as guaifenesin; pseudoephedrine hydrochloride by ACTAVIS LABS FL on May 27th, 2015.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE?
  • What are the global sales for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE?
  • What is Average Wholesale Price for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE?
Summary for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE
Recent Clinical Trials for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dr. Reddy's Laboratories LimitedPhase 1
Reckitt Benckiser LLCPhase 4
Reckitt Benckiser Inc.Phase 4

See all GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE clinical trials

Pharmacology for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

US Patents and Regulatory Information for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Labs Fl GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE guaifenesin; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 091071-001 May 27, 2015 OTC No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Granules GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE guaifenesin; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 216082-002 Aug 22, 2022 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma Ltd GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE guaifenesin; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 213203-001 Mar 25, 2020 OTC No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Sun Pharm Inds Inc GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE guaifenesin; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 212542-001 Apr 28, 2020 OTC No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Granules GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE guaifenesin; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 216082-001 Aug 22, 2022 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Actavis Labs Fl GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE guaifenesin; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 091071-002 May 27, 2015 OTC No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma Ltd GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE guaifenesin; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 213203-002 Mar 25, 2020 OTC No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.